Nureca Limited Reports Profit Turnaround and ₹100 Crore Capex Approval

Nureca Limited reported a significant turnaround in its financial performance for the year ended March 31, 2026. The company's standalone profit shifted to ₹0.297 crore from a loss of ₹0.668 crore in the previous fiscal year. On a consolidated basis, profit after tax surged by 145.9% to ₹2.08 crore from ₹0.846 crore in FY25.

Reader Takeaway: Profitability achieved with strong revenue growth; ₹100 crore capex signals aggressive expansion.

What just happened

Nureca Limited announced its audited financial results for the fiscal year ended March 31, 2026. Key highlights include a standalone profit of ₹0.297 crore, marking a return to profitability. The consolidated profit after tax saw a substantial increase of 145.9% to ₹2.08 crore. The company's standalone revenue grew by 28.4% to ₹147.21 crore, while consolidated revenue rose by 34.0% to ₹146.96 crore.

Additionally, the Board of Directors approved an incremental capital expenditure of up to ₹100 crore for plant and machinery to manufacture additional medical devices, healthcare consumables, and hygiene products. The Board also approved the purchase of adjoining land for future expansion.

Why this matters

The financial turnaround to profitability is a positive signal for investors, indicating improved operational efficiency and market demand. The significant capital expenditure plan underscores management's confidence in the growth prospects of the medical device and healthcare consumables sector. This expansion could lead to increased production capacity and market share in the coming years.

The backstory

Nureca Limited is known for its range of healthcare and wellness products. In the previous fiscal year (FY25), the company reported a standalone loss, making the current year's return to profitability a key development. The company has been focusing on expanding its product portfolio and manufacturing capabilities.

What changes now

The approved capital expenditure will drive the expansion of manufacturing facilities for medical devices and related products. This is expected to boost production volumes and potentially revenue in the future. The leadership changes, including the appointment of a new CFO, will be closely watched for continuity in financial strategy and execution.

Risks to watch

While the capex plan is positive, execution risks associated with large-scale expansions, including timely completion and cost overruns, need monitoring. Changes in regulatory landscapes for medical devices and intense market competition could also pose challenges. The transition to a new CFO might require a period of adjustment.

Peer comparison

Nureca operates in the medical devices and healthcare consumables market. Companies like Poly Medicure, C-RAM, and Opto Circuits (India) are also active in this space. While specific peer financial data for FY26 is not immediately available, Nureca's reported growth and profitability improvement position it positively within the sector's recovery and expansion trends.

Context metrics (time-bound)

• Standalone Revenue Growth: +28.4% (FY26 vs FY25)
• Standalone Profit/(Loss): ₹0.297 crore (FY26) vs ₹-0.668 crore (FY25)
• Consolidated Revenue Growth: +34.0% (FY26 vs FY25)
• Consolidated Profit After Tax: ₹2.08 crore (FY26) vs ₹0.846 crore (FY25)
• Approved Capex: Up to ₹100 crore

What to track next

Investors will be keen to track the progress of the ₹100 crore expansion project, its timelines, and its impact on production and revenue. Monitoring the company's profitability trajectory and market share gains in the medical device segment will also be crucial. The smooth integration of the new CFO and their contribution to financial management will be important to observe.